Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Drug Resistance Updates is Scopus-indexed (Q1, CiteScore 29.1), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Churchill Livingstone.
Checked against the index lists dated .
ISSN 1368-7646Verify ISSN ↗1532-2084Verify ISSN ↗
Publisher: Churchill Livingstone
Cost to publish: About US$5,410 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 1 / 278 | 99th | Q1 |
| Pharmacology | 4 / 328 | 98th | Q1 |
| Infectious Diseases | 5 / 361 | 98th | Q1 |
| Oncology | 15 / 428 | 96th | Q1 |
| Cancer Research | 12 / 233 | 95th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1998–present, best quartile Q1, CiteScore 29.1.
Drug Resistance Updates is Q1 in Pharmacology (medical) (rank 1 of 278), Q1 in Pharmacology (rank 4 of 328) and Q1 in Infectious Diseases (rank 5 of 361), by CiteScore 2025. It is ranked in 5 subject areas in all.
Drug Resistance Updates is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 29.1, which places it in quartile Q1 at the 99th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 5.279, quartile Q1, with an H-index of 148.
The publisher lists an article processing charge of about US$5,410 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Drug Resistance Updates is published by Churchill Livingstone. Its print ISSN is 1368-7646 and its online ISSN is 1532-2084.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Drug Resistance Updates has an h-index of 161 and a 2-year mean of 15.75 citations per paper (OpenAlex). Its Scopus CiteScore is 29.1, quartile Q1. On 2-year citations it ranks #2 of 271 Scopus journals in Pharmacology (medical).
Drug Resistance Updates published 110 papers in 2025; its busiest recent year was 2024 with 115. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from China (60%), United States (13.3%) and South Korea (4%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 1 retracted paper is recorded (0.8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.